LTFS
ALLO icon

Ladenburg Thalmann Financial Services’s Allogene Therapeutics ALLO Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$4K Sell
126
-636
-83% -$17.5K ﹤0.01% 4833
2019
Q3 		$21K Hold
762
– – ﹤0.01% 4006
2019
Q2 		$20K Hold
762
– – ﹤0.01% 4043
2019
Q1 		$22K Buy
+762
New +$22.1K ﹤0.01% 3929

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ALLO Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Allogene Therapeutics (ALLO) stake by 83% in Q4 2019, selling an estimated $17.5K and leaving 126 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #4833.

Ladenburg Thalmann Financial Services first reported a position in ALLO in Q1 2019 and has held it in 4 quarters since. The position peaked at $22K in Q1 2019. 116 funds tracked by Wall St. Rank hold ALLO as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 126 shares of Allogene Therapeutics worth $4K as of Q4 2019.
  • Ladenburg Thalmann Financial Services sold 636 Allogene Therapeutics shares in Q4 2019, an estimated $17.5K.
  • Allogene Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4833 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 4 quarters since.
  • Ladenburg Thalmann Financial Services's Allogene Therapeutics position peaked at $22K in Q1 2019.
  • 116 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.